Tirzepatide (15mg)
Tirzepatide is a dual GLP-1/GIP agonist. The 15 mg vial is ideal for maintenance doses of 10–15 mg/week, reducing vial count. A half-life of ~5 days allows for weekly subcutaneous administration.
Reviewed by the AllPeptides.eu Editorial Team·Last reviewed: 2026-06-16
Educational information. Not medical advice, and no efficacy claim is implied. Regulatory approval is not a use recommendation by AllPeptides.eu.
⚠️ For informational/educational purposes only. Not medical advice. We do not sell any products. Self-treatment carries serious risks — consult a healthcare professional. Disclaimer
Research monograph
See the full Tirzepatide encyclopedia page with mechanism, evidence tier, related variants and research context.
How It Works
Tirzepatide simultaneously activates GLP‑1 and GIP receptors, enhancing glucose-dependent insulin secretion, suppressing glucagon, slowing gastric emptying, and reducing appetite via central mechanisms.
Quick Start
- Reconstitution: Add 3.0 mL bacteriostatic water → 5.0 mg/mL concentration.
- Typical Weekly Range: 2.5–15 mg once weekly.
- Storage: Lyophilized: −20 °C· reconstituted: 2–8 °C· use within 28 days.
Typical / Titration Approach (3 mL = 5.0 mg/mL)
Route: Subcutaneously | Frequency: Once weekly
| Week | Dose | Units (per injection) |
|---|---|---|
| Weeks 1–4 | 2.5 mg | 50 Units (0.50 mL) |
| Weeks 5–8 | 5 mg | 100 Units (1.00 mL) |
| Weeks 9–12 | 7.5 mg | 2 × 75 Units (0.75 mL) |
| Weeks 13–16 | 10 mg | 2 × 100 Units (1.00 mL) |
| Weeks 17+ | 15 mg | 3 × 100 Units (1.00 mL) |
Studies report administration once weekly subcutaneously. For doses >1.0 mL, split into multiple injections. Increase every 4 weeks.
Related compounds
Reconstitution Steps
- Draw up 3.0 mL of bacteriostatic water.
- Inject slowly down the side of the vial; avoid foaming.
- Gently swirl until dissolved.
- Note date and refrigerate at 2–8 °C.
Protocol Overview
- Objective: Glycemic control and weight management via dual GLP-1/GIP activation.
- Schedule: Weekly subcutaneous injection for 12–16+ weeks.
- Storage: Lyophilized frozen; reconstituted refrigerated.
Dosing Protocol
- Initiation: 2.5 mg/week for 4 weeks.
- Titration: +2.5 mg every 4 weeks.
- Maintenance: 5–15 mg weekly.
- Frequency: Once weekly.
- Break between cycles: After completing the cycle, a 4–8 week washout period is recommended. Tirzepatide has a half-life of ~5 days—sufficient clearance time is required before a new cycle.
Washout & Cycle Restart
When can I restart?
After completing the cycle, a 4–8 week washout period is recommended. Tirzepatide has a half-life of ~5 days—sufficient clearance time is required before a new cycle.
Minimum wait period: 4 weeks
Storage Instructions
- Lyophilized: −20 °C.
- Reconstituted: 2–8 °C; use within 28 days.
- Allow to reach room temperature before opening.
Important Notes
- For doses >1 mL, split into multiple injections.
- GI side effects are reduced with gradual titration.
Potential Benefits & Side Effects
Potential Benefits:
- Significant reductions in HbA1c.
- Weight loss up to ~11 kg more than GLP-1 mono-agonists.
- Improvement in cardiovascular markers.
Potential Side Effects:
- GI: Nausea, diarrhea, constipation — mild and dose-dependent.
- Mild injection site reactions.
⚠️ Serious Warnings & Long-Term Risks
The following warnings are based on published literature, FDA labels, and post-marketing surveillance. They do not constitute medical advice. Consult a healthcare professional.
Thyroid C-cell tumors (medullary thyroid carcinoma)
Same warning as GLP-1 RAs. C-cell tumors in rodents. Contraindicated in MTC/MEN 2.
📄 FDA Boxed Warning — Mounjaro® LabelAcute pancreatitis
Risk of acute pancreatitis. Reported in post-marketing surveillance.
📄 FDA Label — Mounjaro®References
- StatPearls (NCBI Bookshelf) — Tirzepatide pharmacology
View Source - NEJM (2022) — Tirzepatide for obesity
View Source - Mounjaro (Tirzepatide) FDA Prescribing Information (2022) — Mounjaro prescribing information
View Source
Recommended Supplements
Vitamin B12 (Methylcobalamin)
Vitamin D3 + K2
Omega-3 Fish Oil (EPA/DHA)
Protein / Collagen
Fiber Supplement (Psyllium)
External Sources & Regulatory Status
Regulatory Approvals
Mounjaro® / Zepbound® · Type 2 diabetes / Obesity (2022)
Mounjaro® · Type 2 diabetes (2022)
Mounjaro® · Type 2 diabetes (2023)
Mounjaro® · Type 2 diabetes (2024)
Mounjaro® · Type 2 diabetes / Obesity (2023)
Mounjaro® · Type 2 diabetes (2023)
Approved worldwide (6+ countries)
Educational information. Not medical advice, and no efficacy claim is implied. Regulatory approval is not a use recommendation by AllPeptides.eu.
Continue Your Research
Explore tools and guides related to this protocol.
Important Disclaimer
The content of this website is provided exclusively for informational and educational purposes within the context of research literature.
Read the full Disclaimer →